#133 - The Battle Over 340B Drug Pricing

We're thrilled to share with you the latest special episode of The ASHHRA Podcast. This episode dives into the critical topic of how recent election results impact the 340B drug pricing program—a program essential for healthcare HR professionals.

Featured Experts:

• Sarah Hearn: Strategic Health Care Market Adviser at RxBenefits
• Rhiannon Klein: National Director of Advocacy for Community Voices for 340B
• Peggy Tighe: Lawyer, Lobbyist, and Legislative Consultant (Principal at Powers Pyles Sutter & Verville PC)

Key Highlights:

Overview of the 340B Program

Peggy Tighe provides a concise history and foundational perspective of the 340B program, established to help specific healthcare providers obtain medications at reduced prices to serve vulnerable communities. Peggy emphasizes the ongoing struggle between the program’s intent and the pressures from pharmaceutical companies and PBMs (Pharmacy Benefit Managers).

Election Impact on Healthcare

Our experts explore how the recent election and new administration might affect the 340B program. Peggy reveals potential threats like the possibility of removing the non-profit status of hospitals, which could have devastating effects on healthcare providers' ability to serve communities.

The Role of Advocacy and Legislation

Rhiannon Klein discusses grassroots advocacy's importance and the organization's role in educating and mobilizing supporters to protect the 340B program. She emphasizes that the fight for fair drug pricing isn’t just a political issue; it’s a moral imperative affecting countless lives.

Contract Pharmacy Restrictions

Both Peggy and Sarah delve into the implications of the Genesis Health case and how contract pharmacy restrictions are undermining the 340B program. They explain how such restrictions harm healthcare providers and the strategies being employed to counteract these changes.

RxBenefits and Healthcare Cost Management

Sarah Hearn explains how RxBenefits is working with healthcare clients to optimize the 340B savings and reduce overall drug costs. Sarah highlights the importance of shifting 340B volume in-house and ensuring compliance to maximize benefits.

Looking Ahead

Our experts leave listeners with actionable insights and resources to better prepare for the changing healthcare landscape. Peggy encourages everyone to stay informed and involved through advocacy organizations like CB 340B, NAC, and Ryan White Clinics for 340B.

Listen Now!

Don’t miss this essential episode filled with expert insights and actionable advice. 

Stay tuned for part 2 of this critical discussion, where we will explore post-election impacts and future strategies for healthcare HR leaders.

Best Regards,

The ASHHRA Podcast Team